Literature DB >> 23296066

Trial data resolve gaps in evidence-based treatment.

Adriaan A Voors1.   

Abstract

In the 2012 ESC guidelines for the management of heart failure, various gaps in the clinical evidence base were identified. Four studies published in 2012 go some way to resolving this data deficit, and treatment recommendations can now be updated accordingly.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296066     DOI： 10.1038/nrcardio.2012.190

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  9 in total

1.  Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Authors:  Luis Miguel Ruilope; Andrej Dukat; Michael Böhm; Yves Lacourcière; Jianjian Gong; Martin P Lefkowitz
Journal:  Lancet       Date:  2010-03-16       Impact factor: 79.321

2.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher; Jeroen J Bax; Helmut Baumgartner; Claudio Ceconi; Veronica Dean; Christi Deaton; Robert Fagard; Christian Funck-Brentano; David Hasdai; Arno Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Theresa McDonagh; Cyril Moulin; Bogdan A Popescu; Zeljko Reiner; Udo Sechtem; Per Anton Sirnes; Michal Tendera; Adam Torbicki; Alec Vahanian; Stephan Windecker; Theresa McDonagh; Udo Sechtem; Luis Almenar Bonet; Panayiotis Avraamides; Hisham A Ben Lamin; Michele Brignole; Antonio Coca; Peter Cowburn; Henry Dargie; Perry Elliott; Frank Arnold Flachskampf; Guido Francesco Guida; Suzanna Hardman; Bernard Iung; Bela Merkely; Christian Mueller; John N Nanas; Olav Wendelboe Nielsen; Stein Orn; John T Parissis; Piotr Ponikowski
Journal:  Eur J Heart Fail       Date:  2012-08       Impact factor: 15.534

3.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

4.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

Authors:  Akshay S Desai; Eldrin F Lewis; Rebecca Li; Scott D Solomon; Susan F Assmann; Robin Boineau; Nadine Clausell; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Sonja McKinlay; Eileen O'Meara; Tamaz Shaburishvili; Bertram Pitt; Marc A Pfeffer
Journal:  Am Heart J       Date:  2011-11-08       Impact factor: 4.749

5.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

Authors:  Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray
Journal:  Lancet       Date:  2012-08-26       Impact factor: 79.321

Review 6.  The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.

Authors:  Ravi V Shah; Akshay S Desai; Michael M Givertz
Journal:  J Card Fail       Date:  2010-01-06       Impact factor: 5.712

7.  Warfarin and aspirin in patients with heart failure and sinus rhythm.

Authors:  Shunichi Homma; John L P Thompson; Patrick M Pullicino; Bruce Levin; Ronald S Freudenberger; John R Teerlink; Susan E Ammon; Susan Graham; Ralph L Sacco; Douglas L Mann; J P Mohr; Barry M Massie; Arthur J Labovitz; Stefan D Anker; Dirk J Lok; Piotr Ponikowski; Conrado J Estol; Gregory Y H Lip; Marco R Di Tullio; Alexandra R Sanford; Vilma Mejia; Andre P Gabriel; Mirna L del Valle; Richard Buchsbaum
Journal:  N Engl J Med       Date:  2012-05-02       Impact factor: 91.245

8.  Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.

Authors:  John R Teerlink; Marco Metra; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Beth Davison Weatherley; Alon Marmor; Amos Katz; Jacek Grzybowski; Elaine Unemori; Sam L Teichman; Gad Cotter
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

9.  Ultrafiltration in decompensated heart failure with cardiorenal syndrome.

Authors:  Bradley A Bart; Steven R Goldsmith; Kerry L Lee; Michael M Givertz; Christopher M O'Connor; David A Bull; Margaret M Redfield; Anita Deswal; Jean L Rouleau; Martin M LeWinter; Elizabeth O Ofili; Lynne W Stevenson; Marc J Semigran; G Michael Felker; Horng H Chen; Adrian F Hernandez; Kevin J Anstrom; Steven E McNulty; Eric J Velazquez; Jenny C Ibarra; Alice M Mascette; Eugene Braunwald
Journal:  N Engl J Med       Date:  2012-11-06       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.